Compass Pathways plc - ADR (CMPS)
NASDAQ
Closed
Oct 7, 2026
Day's Range
11.4552 wk Range
4.88Overview - CMPS - Compass Pathways plc - ADR
Key Statistics
Valuation
Enterprise Value
1.34B
P/E (Trailing)
‪-3.86‬
P/E (Forward)
‪-8.33‬
PEG Ratio
‪-0.01‬
Price / Book
‪19.18‬
EV / EBITDA
‪-7.24‬
Profitability
Profit Margin
‪0.00%‬
Operating Margin
‪0.00%‬
Return on Assets
‪-29.08%‬
Return on Equity
‪-319.06%‬
Ownership
Shares Outstanding
134.94M
Float
106.96M
Short % of Shares Outstanding
‪11.14%‬
Held by Insiders
‪7.62%‬
Held by Institutions
‪68.55%‬
Price stats
Beta
‪2.54‬
50-Day Avg
‪13.36‬
200-Day Avg
‪9.88‬
Dividends
Payout Ratio
‪0.00%‬
Analyst Consensus
16 analysts
Shariah Compliance
Report Date: Feb 17, 2025
Screened by Zoya using the AAOIFI methodology.
Market Cap - CMPS - Compass Pathways plc - ADR
Peers - CMPS - Compass Pathways plc - ADR
Peer Comparison
Compared with companies in Medical Care Facilities listed on NASDAQ.
Profile Summary - CMPS - Compass Pathways plc - ADR
About
Compass Pathways plc - ADR is a clinical-stage biotechnology company focused on mental health care. Compass Pathways develops COMP360, a proprietary synthetic psilocybin therapy being studied for treatment-resistant depression and other psychiatric conditions, including post-traumatic stress disorder and anorexia…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Shariah compliance data provided by Zoya. Charting by TradingView.
Last updated:
